Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (21H00184, 21H05612, 21H02846)
Article History
Received: 14 March 2022
Revised: 17 March 2022
Accepted: 22 March 2022
First Online: 6 April 2022
Competing interests
: YH and TS have no conflict of interest. KH is the inventor of filed patent applications on “The use of <i>R</i>-Ketamine in the treatment of psychiatric diseases”, “(<i>S</i>)-norketamine and salt thereof as pharmaceutical”, “<i>R</i>-Ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder”, “Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases”, and “<i>R</i>-Ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder” by the Chiba University. KH has also received speakers’ honoraria, consultant fee, or research support from Abbott, Meiji Seika Pharma, Daiichi-Sankyo, Dainippon-Sumitomo, Taisho, Otsuka, Murakami Farm and Perception Neuroscience.
Free to read: This content has been made available to all.